Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases

by Toshihide Takeuchi, Yoshitaka Nagai
Published 2017-10-01

E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.

by Ryusuke Sakai, Mari Suzuki, Morio Ueyama, Toshihide Takeuchi, Eiko N Minakawa, Hideki Hayakawa, Kousuke Baba, Hideki Mochizuki, Yoshitaka Nagai
Published 2019-01-01

Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.

by H Akiko Popiel, Toshihide Takeuchi, Hiromi Fujita, Kazuhiro Yamamoto, Chiyomi Ito, Hiroshi Yamane, Shin-ichi Muramatsu, Tatsushi Toda, Keiji Wada, Yoshitaka Nagai
Published 2012-01-01